公开(公告)号：US20240335498A1

公开(公告)日：2024-10-10

申请号：US18297841

申请日：2023-04-10

申请人： Xygenyx Inc.

发明人： Alexy Goldstein

IPC分类号： A61K38/06 ,  A61K8/04 ,  A61K8/44 ,  A61K8/64 ,  A61K8/67 ,  A61K8/9794 ,  A61K9/00 ,  A61K9/06 ,  A61K31/07 ,  A61K31/198 ,  A61K36/886 ,  A61Q19/00

CPC分类号： A61K38/06 ,  A61K8/042 ,  A61K8/44 ,  A61K8/64 ,  A61K8/671 ,  A61K8/9794 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/07 ,  A61K31/198 ,  A61K36/886 ,  A61Q19/00 ,  A61K2800/10

摘要： A composition comprising an aqueous gel with therapeutically effective amounts of lysine, aloe vera gel, retinol, and a synthetic peptide. The synthetic peptide may comprise palmitoyl tripeptide-5 or tripeptide-10 citrulline, and the addition of a therapeutically effective amount of a plurality of ceramides may also be used.

公开(公告)号：US20240293500A1

公开(公告)日：2024-09-05

申请号：US18574671

申请日：2022-06-28

申请人： Korea University Research and Business Foundation

发明人： Min Jeong SHIN ,  In Hyeok JEONG

IPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61P35/00

CPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61P35/00

摘要： The present invention relates to a novel anticancer peptide. The anticancer peptide inhibits cancer cell proliferation and metastasis, induces cell death, and relieves drug resistance, and thus may be utilized for an anticancer use and an anticancer adjuvant.

公开(公告)号：US12077605B2

公开(公告)日：2024-09-03

申请号：US18157293

申请日：2023-01-20

申请人： ANIXA BIOSCIENCES, INC.

发明人： Wolfgang Richter ,  Muhammad Abbas ,  Lutz Weber ,  Amit Kumar

IPC分类号： C07K5/087 ,  A61K31/245 ,  A61K31/404 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K36/746 ,  A61K38/06 ,  A61P31/14

CPC分类号： C07K5/0812 ,  A61K31/245 ,  A61K31/404 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K36/746 ,  A61K38/06 ,  A61P31/14

摘要： Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

公开(公告)号：US12070468B2

公开(公告)日：2024-08-27

申请号：US17984734

申请日：2022-11-10

申请人： The Trustees of Columbia University in the City of New York

发明人： Carrie J. Shawber ,  June K. Wu ,  Ajit Muley

IPC分类号： A61K31/145 ,  A61K31/407 ,  A61K31/501 ,  A61K31/69 ,  A61K38/06 ,  A61K38/07 ,  A61P9/14

CPC分类号： A61K31/69 ,  A61K31/145 ,  A61K31/407 ,  A61K31/501 ,  A61K38/06 ,  A61K38/07 ,  A61P9/14

摘要： Provided herein are methods and compositions for treating and preventing vascular malformations including lymphatic, venous, capillary, arteriovenous, and combinations thereof. Methods of treatment and prevention include the administration of proteasome inhibitors, omipalisib, disulfiram, and agents which target genes in the PI3K/AKT/mTOR or RAS/RAF/MAPK pathways, including but not limited to Pik3ca, Pik3r3, Tsc2, Rasa1, Map2k2, and Glmn.

公开(公告)号：US12048688B2

公开(公告)日：2024-07-30

申请号：US18086958

申请日：2022-12-22

申请人： Purdue Pharmaceutical Products L.P.

发明人： Thomas Jorg Mehrling ,  Enrique Maria Ocio

IPC分类号： A61K31/4184 ,  A61K31/407 ,  A61K31/427 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/573 ,  A61K31/58 ,  A61K31/69 ,  A61K38/05 ,  A61K38/06 ,  A61K39/395 ,  A61K45/06

CPC分类号： A61K31/4184 ,  A61K31/407 ,  A61K31/427 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/573 ,  A61K31/58 ,  A61K31/69 ,  A61K38/05 ,  A61K38/06 ,  A61K39/3955 ,  A61K45/06 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/58 ,  A61K2300/00 ,  A61K31/4184 ,  A61K2300/00

摘要： The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof:




to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.

公开(公告)号：US12011476B2

公开(公告)日：2024-06-18

申请号：US15931809

申请日：2020-05-14

申请人： The University of Vermont and State Agricultural College

发明人： Yvonne M. Janssen-Heininger ,  Vikas Anathy

IPC分类号： A61K38/12 ,  A61K31/197 ,  A61K31/425 ,  A61K31/437 ,  A61K31/713 ,  A61K38/06 ,  A61K38/16 ,  A61K38/45 ,  A61K45/06 ,  C12N15/113

CPC分类号： A61K38/12 ,  A61K31/197 ,  A61K31/425 ,  A61K31/437 ,  A61K31/713 ,  A61K38/06 ,  A61K38/164 ,  A61K38/45 ,  A61K45/06 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y205/01018 ,  C12Y503/04001 ,  A61K31/425 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00

摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

公开(公告)号：US20240180996A1

公开(公告)日：2024-06-06

申请号：US18405561

申请日：2024-01-05

申请人： Alastin Skincare, Inc.

发明人： Alan David WIDGEROW ,  John A. GARRUTO

IPC分类号： A61K38/06 ,  A61K8/73 ,  A61K9/00 ,  A61K9/127 ,  A61K31/685 ,  A61K38/07 ,  A61K38/08 ,  A61K38/40 ,  A61K45/06 ,  A61Q19/08

CPC分类号： A61K38/06 ,  A61K8/735 ,  A61K9/0014 ,  A61K9/127 ,  A61K31/685 ,  A61K38/07 ,  A61K38/08 ,  A61K38/40 ,  A61K45/06 ,  A61Q19/08 ,  A61K2800/91

摘要： Compositions and methods for improving bruising, stimulating elastin and/or collagen production, stimulating intrinsic hyaluronic acid production, stimulating adipogenesis, reducing inflammation, or combinations thereof are provided herein. Compositions and methods described herein may be used in conjunction with use of a filler (e.g., a hyaluronic acid filler).

公开(公告)号：US11951148B1

公开(公告)日：2024-04-09

申请号：US17498647

申请日：2021-10-11

申请人： Fleurir ABX LLC

发明人： John Lee Pace

IPC分类号： A61K38/06 ,  A61K9/00 ,  A61K31/166 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/424 ,  A61K31/4545 ,  A61K38/05 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC分类号： A61K38/06 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0073 ,  A61K31/166 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/424 ,  A61K31/4545 ,  A61K38/05 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30

摘要： New improved formulations are described, comprising at least one composition, with or without another composition (at least one second composition), in which the at least one composition, a first composition, is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The at least one second composition may be a streptogramin. The first composition, alone or in combination with another, may be used to improve and/or treat a wide variety of bacterial infections, providing, on its own better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other or alternative inhibitors of lipid A deacetylase, as well as no expected cardiotoxicity. When provided to a susceptible microorganism as a combination described herein, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations). Such combinations may also be provided via any route(s) of administration, and in any pharmaceutically acceptable form known, available, and/or suitable for use, such as to a subject in need thereof.

公开(公告)号：US20240075027A1

公开(公告)日：2024-03-07

申请号：US18320470

申请日：2023-05-19

申请人： Auburn University

发明人： Amit Kumar Mitra ,  Harish Kumar

IPC分类号： A61K31/498 ,  A61K31/454 ,  A61K31/69 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61P35/00

CPC分类号： A61K31/498 ,  A61K31/454 ,  A61K31/69 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61P35/00

摘要： The present invention relates to compositions comprising clofazimine and methods for treating cancer. In various embodiments, the compositions and methods further comprise a proteasome inhibitor and/or immunomodulatory drug. The compositions and methods of the present invention may be used for naïve cancers as well as those that have developed resistance to proteasome inhibitors and/or immunomodulatory drugs.

公开(公告)号：US20230414699A1

公开(公告)日：2023-12-28

申请号：US18248137

申请日：2021-10-08

申请人： MC2 Therapeutics Ltd

发明人： Torkil Menne ,  Johan Selmer ,  Jesper Lange ,  Jon Bondebjerg ,  Michelle Georgiou

IPC分类号： A61K38/05 ,  A61K38/06 ,  A61K31/198 ,  A61K31/4985 ,  A61K31/15 ,  A61P17/00

CPC分类号： A61K38/05 ,  A61K38/06 ,  A61P17/00 ,  A61K31/4985 ,  A61K31/15 ,  A61K31/198

摘要： Provided is a pharmaceutical composition which comprises a nucleophilic compound capable of inhibiting carbamylation, for use in the treatment of a condition involving cutaneous or connective tissue damage. A method for treating a condition involving cutaneous or connective tissue damage in a patient, is also provided, said method comprising administering a said pharmaceutical composition to said patient.